In the BioHarmony Drug Report Database
Daratumumab
Darzalex (daratumumab) is an antibody pharmaceutical. Daratumumab was first approved as Darzalex on 2015-11-16. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
Trade Name
|
Darzalex |
|---|---|
Common Name
|
daratumumab |
ChEMBL ID
|
CHEMBL1743007 |
Indication
|
multiple myeloma |
Drug Class
|
Monoclonal antibodies |
Image (chem structure or protein)
